BiotechTube

REGN475/SAR164877 + Placebo (for REGN475/SAR164877)

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Abdominal Pain Upper

Conditions

Abdominal Pain Upper

Trial Timeline

Dec 1, 2009 → Jan 1, 2011

NCT ID
NCT01001923

About REGN475/SAR164877 + Placebo (for REGN475/SAR164877)

REGN475/SAR164877 + Placebo (for REGN475/SAR164877) is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Abdominal Pain Upper. The current trial status is terminated. This product is registered under clinical trial identifier NCT01001923. Target conditions include Abdominal Pain Upper.

What happened to similar drugs?

6 of 20 similar drugs in Abdominal Pain Upper were approved

Approved (6) Terminated (1) Active (14)
✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
✅Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalinPfizerApproved
✅Tigecycline + Imipenem/cilastatinPfizerApproved
✅tigecyclinePfizerApproved
✅Fibrinogen concentrate + Fresh Frozen PlasmaCSLApproved
✅Sevoflurane + propofol + remifentanilBaxterApproved
🔄PD-1 Inhibitors + Irinotecan + Capecitabine tabletsJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01001923Phase 2Terminated
NCT01001715Phase 2Terminated

Competing Products

20 competing products in Abdominal Pain Upper

See all competitors
ProductCompanyStageHype Score
PD-1 Inhibitors + Irinotecan + Capecitabine tabletsJiangsu Hengrui MedicinePhase 3
36
HR021618 + PlaceboJiangsu Hengrui MedicinePhase 2
35
Ticagrelor + PlaceboAstraZenecaPhase 2
35
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactamMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
40
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mgMerckPhase 3
40
CXA-201 and metronidazole + MeropenemMerckPhase 3
40
Imipenem+Cilastatin/RelebactamMerckPhase 3
40
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
35
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral TabletMerckPhase 2/3
42
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 WeeksMerckPhase 3
40
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
40
LYS228 + Standard of care therapyNovartisPhase 2
27
ACZ885 + PlaceboNovartisPhase 2
27
Evolocumab + PlaceboAmgenPhase 1
36
tigecyclinePfizerPhase 3
40
recombinant human growth hormonePfizerPhase 3
40
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalinPfizerApproved
35